Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.
ncRNA name
hsa-miR-202
Specific or universal ncRNAs
Universal ncRNAs
Class
MicroRNA
Biomarker
No
Biomarker application
Upstream regulatory factors
Not available
Downstream target
Ras/MAPK pathway
Cancer name
Non-Small Cell Lung Cancer
Cancer site
Lung
Treatment type
Chemotherapy
Drug
Cisplatin
Impact of wild-type ncRNA on chemotherapy resistance
Down
Impact of knockdown of ncRNA on chemotherapy resistance
Impact of overexpression of ncRNA on chemotherapy resistance
ncRNA differential expression in
cancer
patients vs. healthy people
Not available
Number of patients
Not available
Male patients
Not available
Female patients
Not available
Age range and number
Not available
PMID
Description
The miR-202/KRas controlled the chemosensitivity of NSCLC by mediating the Ras/MAPK pathway. Thus, the combination of platinum-based drugs with miR-202 may represent a novel strategy to enhance the antitumor effect against NSCLC.
Tissue resource
primary non-small cell lung cancer tumor tissues and their corresponding paracancerous
non-small cell lung cancer cell lines NCI-H441
non-small cell lung cancer cell lines A549
Experiment
qRT-PCR,Western blot,Luciferase reporter assay
Institute
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
American Type Culture Collection
Country
China
USA
Continent
Asia
North American
Institutes for Systems Genetics, West China Hospital
Copyright @ 2022 ISG. All Rights Reserved.